Shunya Ikeda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3289076/publications.pdf

Version: 2024-02-01

516710 1,417 76 16 citations h-index papers

g-index 78 78 78 1594 docs citations times ranked citing authors all docs

361022

35

#	Article	IF	CITATIONS
1	Primary herpetic oropharyngitis in adults: Differences in clinical features between Herpes simplex virus type 1 and type 2. A retrospective study. Clinical Otolaryngology, 2022, 47, 328-330.	1.2	O
2	Depressive symptoms in workers with high autistic trait scores according to job stress type. Industrial Health, 2022, 60, 578-588.	1.0	2
3	Misconceptions and Rumors about Ebola Virus Disease in Sub-Saharan Africa: A Systematic Review. International Journal of Environmental Research and Public Health, 2022, 19, 4714.	2.6	7
4	Improvement in prescriptions while maintaining overall health outcomes: a prospective observational study conducted in Japanese facilities for older people. BMC Geriatrics, 2022, 22, 323.	2.7	0
5	Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents. Psychological Medicine, 2022, 52, 2822-2834.	4.5	4
6	Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review. Pharmacoeconomics, 2021, 39, 81-97.	3. 3	15
7	Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries. PharmacoEconomics - Open, 2021, 5, 57-69.	1.8	8
8	The effect of perceived social support on psychological distress and life satisfaction among Nepalese migrants in Japan. PLoS ONE, 2021, 16, e0246271.	2.5	19
9	Malaria rapid diagnostic test (HRP2/pLDH) positivity, incidence, care accessibility and impact of community WASH Action programme in DR Congo: mixed method study involving 625 households. Malaria Journal, 2021, 20, 117.	2.3	0
10	Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 235-245.	1.4	8
11	Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan. Medical Decision Making, 2021, 41, 597-606.	2.4	41
12	Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. Value in Health Regional Issues, 2021, 24, 82-89.	1.2	6
13	Impact of the Severity of Alzheimer's Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan. Journal of Alzheimer's Disease, 2021, 81, 367-374.	2.6	10
14	Economic Burden of Alzheimer's Disease Dementia in Japan. Journal of Alzheimer's Disease, 2021, 81, 309-319.	2.6	19
15	Epidemiology and burden of illness of seasonal influenza among the elderly in Japan: A systematic literature review and vaccine effectiveness metaâ€analysis. Influenza and Other Respiratory Viruses, 2021, 15, 293-314.	3.4	17
16	Mortality due to HIV/AIDS in Viet Nam: time trend and related socio-economic status in some populations and periods from 2005 to 2014. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 843-849.	1.2	0
17	An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 455-471.	1.4	3
18	Dimensions of women's empowerment on access to skilled delivery services in Nepal. BMC Pregnancy and Childbirth, 2020, 20, 622.	2.4	20

#	Article	IF	Citations
19	Development of a multiplicative, multi-attribute utility function and eight single-attribute utility functions for the Health Utilities Index Mark 3 in Japan. Journal of Patient-Reported Outcomes, 2020, 4, 23.	1.9	5
20	Local perspectives on Ebola during its tenth outbreak in DR Congo: A nationwide qualitative study. PLoS ONE, 2020, 15, e0241120.	2.5	18
21	Fruit and Vegetable Intake and Stomach Cancer among Male Adults: A Case-Control Study in Northern Viet Nam. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2109-2115.	1.2	5
22	Systematic literature review of clinical outcomes in adults with metastatic or advanced synovial sarcoma. Future Oncology, 2020, 16, 2997-3013.	2.4	2
23	Autistic and Attention Deficit/Hyperactivity Disorder Traits Are Associated with Suboptimal Performance among Japanese University Students. JMA Journal, 2020, 3, 216-231.	0.8	4
24	Gastric cancer mortality rates by occupation and industry among male and female workers aged 25–64 years in Japan. Industrial Health, 2020, 58, 554-564.	1.0	7
25	Selenium supplementation in HIV-infected individuals: A systematic review of randomized controlled trials. Clinical Nutrition ESPEN, 2019, 34, 1-7.	1.2	23
26	Assessing the prevalence of hepatitis B virus infection among health care workers in a referral hospital in Kisantu, Congo DR: a pilot study. Industrial Health, 2019, 57, 621-626.	1.0	7
27	Environmental and sociodemographic factors associated with household malaria burden in the Congo. Malaria Journal, 2019, 18, 53.	2.3	21
28	Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. Journal of Gastroenterology, 2019, 54, 558-570.	5.1	59
29	Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). Journal of Pharmaceutical Health Care and Sciences, 2018, 4, 31.	1.0	8
30	2.Policy Application of Health Technology Assessment : Economic Evaluation of Vaccination . Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2018, 23, 11-17.	0.0	0
31	Serum selenium levels in tuberculosis patients: A systematic review and meta-analysis. Journal of Trace Elements in Medicine and Biology, 2018, 50, 257-262.	3.0	12
32	Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more costâ€effective as the firstâ€line treatment?. International Journal of Urology, 2018, 25, 863-870.	1.0	13
33	Cost-effectiveness Analysis for Health Policy Making in Japan. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, CL-6.	0.0	0
34	A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS 2 score in Japan. Journal of Cardiology, 2017, 69, 89-97.	1.9	8
35	New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations. Health Policy, 2017, 121, 836-841.	3.0	43
36	Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan. Value in Health, 2017, 20, 372-378.	0.3	119

#	Article	IF	CITATIONS
37	A Clinical Study of Cases of Singers with Voice Disorder Caused by Nasopharyngitis. Japan Journal of Logopedics and Phoniatrics, 2017, 58, 333-338.	0.1	O
38	Economic evaluation of Kampo therapy. Traditional & Kampo Medicine, 2016, 3, 151-156.	0.6	2
39	Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan. Value in Health, 2016, 19, 648-654.	0.3	180
40	The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan. Pharmacoeconomics, 2016, 34, 1005-1014.	3.3	8
41	Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Quality of Life Research, 2016, 25, 707-719.	3.1	229
42	Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data. BMC Health Services Research, 2015, 16, 6.	2.2	9
43	Predicting failure to follow-up screened high blood pressure in Japan: a cohort study. Journal of Public Health, 2015, 37, 498-505.	1.8	9
44	Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy. BMC Health Services Research, 2015, 16, 2.	2.2	15
45	Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults. BMC Health Services Research, $2015,15,2.$	2.2	14
46	Introduction and Assessment of Usage of Probabilistic Sensitivity Analysis in Health Economic Evaluation /b>. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2015, 19, 91-99.	0.0	0
47	Prescribing Pattern of Anti-Parkinson Drugs in Japan: A Trend Analysis from 2005 to 2010. PLoS ONE, 2014, 9, e99021.	2.5	33
48	Considering economic analyses in the revision of the preventive vaccination law: A new direction for health policy-making in Japan?. Health Policy, 2014, 118, 127-134.	3.0	8
49	Predictors of hyperglycaemic individuals who do not follow up with physicians after screening in Japan: A cohort study. Diabetes Research and Clinical Practice, 2014, 105, 176-184.	2.8	12
50	The Health Technology Assessment Environment in Mainland China, Japan, South Korea, and Taiwanâ€"Implications for the Evaluation of Diabetes Mellitus Therapies. Value in Health Regional Issues, 2014, 3, 108-116.	1.2	18
51	Investigation of Evidence Sources for Health-Related Quality of Life in Cost-Utility Analysis of Pharmaceuticals in Japan. Value in Health Regional Issues, 2014, 3, 190-196.	1.2	4
52	Extending role by Japanese pharmacists after training for performing vital signs monitoring. Pharmacy Practice, 2014, 12, 0-0.	1.5	1
53	WTP for a QALY and health states: More money for severer health states?. Cost Effectiveness and Resource Allocation, 2013, 11, 22.	1.5	81
54	A Draft of Socio-economic Evaluation Guideline for Pharmaceuticals and Medical Devices Based on Japanese Experts Consensus: Potentials and Issues. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2011, 16, 21-26.	0.0	1

#	Article	IF	CITATIONS
55	Cost-effectiveness Analysis of Pregabalin for Treatment of Peripheral Neuropathic Pain. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2011, 16, 1-9.	0.0	3
56	Costâ€effectiveness analysis of voglibose for prevention of type 2 diabetes mellitus in Japanese patients with impaired glucose tolerance. Journal of Diabetes Investigation, 2010, 1, 252-258.	2.4	7
57	Identification of Adverse Events in Inpatients: Results of a Preliminary Survey in Japan. Asian Pacific Journal of Disease Management, 2010, 4, 49-53.	0.3	1
58	Development of Risk Simulation Software for Outcome Prediction and Economic Assessment of Diabetes Mellitus. Asian Pacific Journal of Disease Management, 2008, 2, 111-118.	0.3	0
59	Clinical and Behavioral Impact of Implementing Community-Based Diabetes Disease Management in Japan. Disease Management and Health Outcomes, 2006, 14, 45-54.	0.4	2
60	Economic Evaluation of Donepezil Treatment for Alzheimer's Disease in Japan. Dementia and Geriatric Cognitive Disorders, 2002, 13, 33-39.	1.5	47
61	Pharmacoeconomic Evaluation in Japanese Pharmaceutical Companies. Drug Information Journal, 1998, 32, 169-174.	0.5	4
62	Japan's Aging Population. Pharmacoeconomics, 1997, 11, 306-318.	3.3	15
63	A Case for the Adoption of Pharmacoeconomic Guidelines in Japan. Pharmacoeconomics, 1996, 10, 546-551.	3.3	19
64	Electrocochleography during Experimental Cochlear Ischemia of the Guinea Pig. Acta Oto-Laryngologica, 1996, 116, 253-256.	0.9	11
65	Nystagmus and Equilibrium Symptom after Removal of Acoustic Neuroma Equilibrium Research, 1995, 54, 327-331.	0.1	0
66	Hearing Recovery and Vestibular Symptoms in Patients with Sudden Deafness and Profound Hearing Loss. Acta Oto-Laryngologica, 1994, 114, 41-44.	0.9	14
67	The usefulness and limitation of the imaging techniques for the diagnosis of acoustic neuroma. Journal of Japan Society for Head and Neck Surgery, 1992, 2, 117-122.	0.0	0
68	The Growth Rate of Acoustic Neuromas. Acta Oto-Laryngologica, 1991, 111, 157-163.	0.9	66
69	Audiological Findings in Acoustic Neuroma. Acta Oto-Laryngologica, 1991, 111, 125-132.	0.9	17
70	Surgical Anatomy for the Extended Middle Cranial Fossa Approach. Acta Oto-Laryngologica, 1991, 111, 41-47.	0.9	6
71	Postoperative Complications in Acoustic Neuroma Surgery by the Extended Middle Cranial Fossa Approach. Acta Oto-Laryngologica, 1991, 111, 75-79.	0.9	18
72	Preoperative Findings and Hearing Preservation in Acoustic Neuroma Surgery. Acta Oto-Laryngologica, 1991, 111, 30-35.	0.9	7

Shunya Ikeda

#	Article	lF	CITATIONS
73	Changes in Clinical Features of Acoustic Neuroma. Acta Oto-Laryngologica, 1991, 111, 120-124.	0.9	8
74	Progression of Hearing Loss in Acoustic Neuromas. Acta Oto-Laryngologica, 1991, 111, 133-137.	0.9	11
75	Long-term observation of hearing in steroid-responsive sensorineural hearing loss Audiology Japan, 1991, 34, 84-90.	0.1	2
76	Acute profound deafness related to immunological impairments Audiology Japan, 1990, 33, 259-265.	0.1	2